Mesenchymal Stem Cell Therapy in Severe COVID-19 in a Young Male Healthcare Worker with Tetralogy of Fallot

Öz

A novel type of coronavirus (SARS-CoV-2), which causesevere acute respiratory syndrome, wasfirst identified in Wuhan,
China at the end of December 2019 and the disease rapidly spread worldwide. COVID-19 may be characterized by a
range of symptoms, mild illness to severe pneumoniae. Cardiovascular diseases increase severity and mortality in COVID-19
patients. Tetralogy of Fallot is the most common cyanotic congenital heart disease. The present case is an adult COVID-19
patient with a history of Tetralogy of Fallot, who is a healthcare worker. High Flow Nasal Oxygen therapy was used due to
respiratory distress. In addition, Mesenchymal Stem Cells were applied while the disease was in critical process. The clinical
and laboratory improvement were observed in the patient from the second day of treatment of Mesenchymal Stem Cells. The
young healthcare worker with a history of Tetralogy of Fallot needed critical care due to COVID-19. Response to the antiviral
treatments given to the patient could not be obtained. High Flow Nasal Oxygen and Mesenchymal Stem Cells were used in
the treatment of the patient.

Anahtar Kelimeler

• COVID-19
• mezenkimal kök hücre
• yüksek akışlı nazal oksijen
• fallot tetralojisi

Fallot Tetralojisi Olan Genç Erkek Sağlık Çalışanının Şiddetli COVID-19’unda Mezenkimal Kök Hücre Tedavisi

Öz

Background: A novel type of coronavirus (SARS- CoV -2), which cause severe acute respiratory syndrome, was first identified in Wuhan, China at the end of December 2019 and the disease rapidly spread worldwide. COVID-19 may be characterized by a range of symptoms; mild illness to severe pneumoniae. Cardiovascular diseases increase severity and mortality in COVID-19 patients. Tetralogy of Fallot (ToF) is the most common cyanotic congenital heart disease. Case presentation: Present case is an adult COVID-19 patient with a history of ToF, who is a healthcare worker. High Flow Nasal Oxygen (HFNO) was used due to respiratory distress. In addition, Mesenchymal Stem Cells (MSCs) were applied while the disease was in critical process. Clinical and laboratory improvement was observed in the patient from the second day of treatment of MSCs. Conclusions: The young healthcare worker with a history of ToF needed critical care due to COVID-19. Response to the antiviral treatments given to the patient could not be obtained. HFNO and MSCs were used in the treatment of the patient. Clinical and laboratory improvement was observed in the patient from the second day of treatment of MSCs.

Anahtar Kelimeler

• Mesenchymal Stem Cell
• COVID19
• HFNO

Kaynakça

1. 1. Lai, C.C., et al., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents, 55(3): p. 105924, (2020)
2. 2. van der Ven, J.P.G., et al., Current outcomes and treatment of tetralogy of Fallot. F1000Res, 8, (2019)
3. 3. Driggin, E., et al., Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol, (2020)
4. 4. Golchin, A., E. Seyedjafari, and A. Ardeshirylajimi, Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Rep, (2020)
5. 5. Alhazzani, W., et al., Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med, (2020)
6. 6. Zhai, P., et al., The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents,: p. 105955, (2020)
7. 7. Leng, Z., et al., Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis, 11(2): p. 216-228,(2020)
8. 8. Simsek Yavuz, S. and S. Unal, Antiviral treatment of COVID-19. Turk J Med Sci, 50(SI-1): p. 611-619, (2020)